Showing 2231-2240 of 4122 results for "".
- La Roche-Posay and George Washington University Publish International Study on Sun Protection Behavior and Skin Cancer Awarenesshttps://practicaldermatology.com/news/la-roche-posay-and-george-washington-university-publish-international-study-on-sun-protection-behavior-and-skin-cancer-awareness/2458327/A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographical inequalities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need
- Scleroderma Treatment Breakthrough? New Study Hints At Way To Slow Skin Fibrosishttps://practicaldermatology.com/news/scleroderma-treatment-breakthrough-new-study-suggests-way-to-slow-skin-fibrosis/2458387/New and ongoing research at Hospital for Special Surgery (HSS) in New York City has identified a possible mechanism behind the fibrosis that occurs in scleroderma – a mechanism that may one day lead to a treatment for the disease. The findings appear in the
- Doctors Welcome VOLBELLA XC for Lipshttps://practicaldermatology.com/news/doctors-welcome-volbella-xc-for-lips/2458401/Allergan’s JUVÉDERM VOLBELLA XC is here. The newly approved filler is now available for lip augmentation and correction of perioral rhytids in adults over the age of 21. Physicians can purchase VOLBELLA XC after completion of an
- Oral Nalbuphine®ER Performs Well in Phase 2 Trial of Prurigo Nodularishttps://practicaldermatology.com/news/oral-nalbuphineer-performs-well-in-from-phase-2-trial-in-prurigo-nodularis/2458403/Trevi Therapeutics, Inc.’s Oral Nalbuphine®ER reduced itch intensity and improved quality of life in prurigo nodularis patients, according to a Phase 2 Trial. Nalbuphine ER is an oral extended release mu receptor an
- Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studieshttps://practicaldermatology.com/news/regeneron-and-sanofis-ad-drug-dupilumab-performs-well-in-phase-iii-studies/2458418/Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in the New England Journal of Medicine in conjunction with a presentation at the European Ac
- New Research Suggests Why PD-1 Blockers Don't Work for All Melanoma Patientshttps://practicaldermatology.com/news/new-research-suggests-why-pd-1-blockers-dont-work-for-all-melanoma-patients/2458645/Immunotherapy using anti-PD-1 antibodies has been a game change for metastatic melanoma patients, but 60 to 70 percent of patients’ melanoma tumors are resistant to the anti-PD-1 antibodies. Now new research out of UCLA suggests that patterns of gene
- Smartphone Microscopes May Aid Skin Cancer Detection in Developing Worldhttps://practicaldermatology.com/news/smartphone-microscopes-may-aid-skin-cancer-detection-in-developing-world/2458648/Smartphone microscopes may improve the detection of skin cancer in developing countries, according to a study in the Archives of Pathology & Laboratory Medicine. Researchers from The
- Take That, Zika! New Wearable Device Protects Against Mosquitoes that Transmit Zikahttps://practicaldermatology.com/news/take-that-zika-new-wearable-device-protects-against-mosquitoes-that-transmit-zika/2458722/OFF!® Clip-On™ repellent device may help keep Zika-carrying mosquitoes at bay, according to an article in the Journal of Medical Entomol
- L'Oréal Debuts Wearable Electronic UV Monitorhttps://practicaldermatology.com/news/loral-debuts-wearable-electronic-uv-monitor/2458740/Earlier this month at the Consumer Electronics Show, L’Oréal unveiled My UV Patch, a stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection. L’Oréal Group’s dermatological skincare brand, La Roche-Posay, i
- Cosmetic Surgery Forum Wraps Seventh Successful Yearhttps://practicaldermatology.com/news/cosmetic-surgery-forum-wraps-seventh-successful-year/2458791/Covering topics from the appropriate use of permanent fillers to the role of spirituality in practice, the seventh annual Cosmetic Surgery Forum (CSF) brought together experts from multiple specialties at the Aria in Las Vegas this month. The three-day program included guidance on practice manage